A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.

NCT07334093 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: B2025-803-01
• Study Type: interventional
• Target: 204
• Locations: 0 countries
• Sites: N/A

Brief Summary

Objective To evaluate the efficacy and safety of hetrombopag plus rhTPO versus hetrombopag monotherapy for CTIT in solid-tumor patients. Participants 204 histologically- or cytologically-confirmed solid-tumor patients with ≥grade 3 thrombocytopenia following anti-cancer treatment. Design Open-label, multicenter, randomized controlled phase II study. Patients are randomized 1:1 into two arms: Experimental arm (N=102): rhTPO 15,000 IU/day subcutaneously + hetrombopag 7.5 mg/day orally, both starting on Day 1 for up to 14 days. Control arm (N=102): Hetrombopag 7.5 mg/day orally starting on Day 1 for up to 14 days. Stopping \& Rescue Rules Stop study drug if PLT ≥100×10⁹/L or rises ≥50×10⁹/L from baseline. If PLT ≤10×10⁹/L or \<20×10⁹/L with bleeding risk, give rescue therapy (platelet transfusion or investigator-chosen alternative). Primary Endpoint Proportion of patients achieving PLT ≥100×10⁹/L or an increase ≥50×10⁹/L from baseline within 14 days of treatment.

Conditions

Cancer Therapy-induced Thrombocytopenia (CTIT)

Outcome Measures

Primary Outcomes (1)

• Proportion of patients achieving PLT ≥100×10⁹/L or an increase ≥50×10⁹/L from baseline within 14 days of treatment.

  within 14 days of treatment.

Secondary Outcomes (1)

• Proportion of patients achieving PLT ≥100×10⁹/L or an increase ≥50×10⁹/L from baseline within 7 days Time to PLT recovery to ≥100×10⁹/L Time to PLT increase ≥50×10⁹/L from baseline Lowest (nadir) platelet count recorded Duration of thrombopoietic therapy

  within 7 days

Study Arms (2)

Experimental arm

EXPERIMENTAL

rhTPO 15,000 IU/day subcutaneously + hetrombopag 7.5 mg/day orally, both starting on Day 1 for up to 14 days.

Drug: rhTPO + hetrombopag

Control arm

ACTIVE COMPARATOR

Hetrombopag 7.5 mg/day orally starting on Day 1 for up to 14 days.

Drug: hetrombopag

Interventions

rhTPO + hetrombopag DRUG

rhTPO 15,000 IU/day subcutaneously + hetrombopag 7.5 mg/day orally, both starting on Day 1 for up to 14 days.

Experimental arm

hetrombopag DRUG

Hetrombopag 7.5 mg/day orally starting on Day 1 for up to 14 days.

Control arm

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18-75 years (inclusive), both sexes eligible.
• Histologically or cytologically confirmed malignant solid tumor (e.g., lung, breast, gastric, colorectal, genitourinary cancers, etc.).
• Currently receiving anti-cancer therapy: chemotherapy, radiotherapy, immuno-chemotherapy, targeted therapy, or combinations.
• Grade ≥3 cancer-therapy-induced thrombocytopenia (PLT \<50×10⁹/L).
• ECOG performance status 0-1.
• Estimated life expectancy ≥12 weeks.
• Women of child-bearing potential must have a negative serum pregnancy test within 7 days before first dose and not be breastfeeding; they must agree to use effective contraception from enrollment through 7 days after the last study drug. Men with partners of child-bearing potential must be surgically sterilized or agree to use effective contraception during the same period and must not donate sperm.
• Willing to participate, able to provide written informed consent, and expected to comply with the study protocol.

You may not qualify if:

• Pregnant or breastfeeding women.
• Individuals unable to understand the nature of the study or who have not given informed consent.
• History of any arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep-vein thrombosis, pulmonary embolism) or clinical/laboratory evidence of a hypercoagulable disorder.
• Cardiac disease within 3 months before screening: grade 3/4 congestive heart failure, arrhythmia requiring medication, myocardial infarction, conditions predisposing to thrombo-embolism (e.g., atrial fibrillation), or QTc prolongation.
• Thrombocytopenia attributed to: concurrent chemoradiotherapy, non-anti-cancer therapy, oxaliplatin-induced sinusoidal injury, definite immune-mediated thrombocytopenia, severe bleeding symptoms, refractory persistent thrombocytopenia, or bone-marrow involvement proven by biopsy in patients with bone metastases.
• Significant hepatic impairment:
• No liver metastases: ALT/AST \> 3 × ULN or TBL \> 3 × ULN.
• Liver metastases present: ALT/AST ≥ 5 × ULN or TBL ≥ 5 × ULN.
• Known or anticipated hypersensitivity/intolerance to TPO-receptor agonists or any ingredient of hetrombopag ethanolamine tablets.
• Concomitant use of other agents that may affect platelet count (e.g., traditional Chinese medicines, other thrombopoietic agents, antiplatelet drugs).
• Receipt of any TPO-receptor agonist (eltrombopag, romiplostim, etc.), recombinant human TPO, or recombinant IL-11 within 1 month before screening.
• Platelet transfusion within 3 days before randomization/first dose.
• Any condition that, in the investigator's opinion, renders the patient unsuitable for enrollment.

Sponsors & Collaborators

• Sun Yat-sen University: lead

MeSH Terms

Interventions

hetrombopag

Central Study Contacts

Yanxia Shi

CONTACT

8602087343486; shiyx@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 31, 2025
• First Posted: January 12, 2026
• Study Start: January 31, 2026
• Primary Completion (Estimated): November 15, 2027
• Study Completion (Estimated): December 15, 2027
• Last Updated: January 12, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share